Evidence map›Paper›PMID 28916619›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Mechanism of Action and Clinical Impact of Ribociclib-Response.

Debu Tripathy, Aditya Bardia, William R Sellers

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Debu TripathyDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. dtripathy@mdanderson.org.
Aditya BardiaDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, Massachusetts.
William R SellersThe Broad Institute and Dana-Farber Cancer Institute, Cambridge, Massachusetts.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9M
NCI NIH HHS K12 CA087723NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsAminopyridinesCyclin-Dependent Kinase 4HumansPurinesAminopyridinesCyclin-Dependent Kinase 4Purinesribociclib

Identifiers

PMID28916619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.